Uncategorized Archives - Page 44 of 87 - PsychedelicNewsWire (PNW)

WednesdayMar 10, 2021 2:00 pm

UC San Diego Researchers to Test Psychedelics Potential in Treating Amputees

The Steven & Alexandra Cohen Foundation recently gave a $1.3 million grant to UC San Diego’s Psychedelics and Health Research Initiative. The grant will be used to finance a clinical trial evaluating the therapeutic potential of psilocybin in managing phantom limb pain. Psilocybin is the active psychedelic compound found in many fungus species, including magic mushrooms. On the other hand, phantom limb pain refers to painful sensations that originate from the part of an individual’s limb that is no longer present, such as an amputated leg. This grant will finance the first placebo-controlled randomized human clinical trial, which will be…

TuesdayMar 09, 2021 3:09 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Upsizes Its Bought Deal Offering Due to Surge in Demand

Cybin's latest offering generated exceptional demand; announces upsize of "bought deal" offering Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments. Cybin appears set for rapid growth as research accelerates, public acceptance grows. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotech company focused on psychedelic therapeutics for various psychiatric and neurological conditions, has announced that it has upsized the terms of its "bought deal" offering due to strong demand. The deal size, previously announced at CDN$20,025,000, has increased to aggregate gross proceeds of CDN$30,015,000 as the underwriters have agreed to purchase 13,340,000 units of the…

TuesdayMar 09, 2021 11:00 am

New Partnership Formed to Create Microneedle Patch to Deliver Psychedelic Medicines

Researchers from Terasaki Institute for Biomedical Innovation (“TIBI”) have designed a microneedle patch that will be used to deliver drugs and is currently being modified for use in micro-dosing psychedelic substances. These compounds include psilocybin mushrooms, LSD and MDMA, all of which have the potential to treat severe pain as well as mental health conditions such as depression and anxiety. The microneedle patch, GeIMA, has been developed using a gelatinous substance, and its surface is made up of tiny microneedles that would contain the drug or drugs to be administered to an individual. When the patch is applied to the…

MondayMar 08, 2021 11:20 am

USF, Partners Obtain DEA Authorization to Study Psychedelics for CNS Disorders

In partnership with the University of South Florida (“USF”) and its chemical screening and purification facility, Psilera Bioscience has acquired approval from the DEA to study psilocin, which is an active psychedelic component found in psilocybin mushrooms and ayahuasca tea, psilocybin and DMT (N,N-dimethyltryptamine). USF and Psilera join other universities across the United States that are also conducting psychedelic research on various psychedelic compounds. Psilera’s objective is to be the pioneer psychedelics company to develop patient-friendly and noninvasive DMT delivery methods. The company’s CSO and co-founder, Dr. Jackie on Salm, explained that the company was focused on developing new delivery…

MondayMar 08, 2021 11:10 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) and Canada House Wellness Group (CSE: CHV) Partner, Bringing New Cannabis 2.0 to More Canadians

Canada House subsidiary Abba Medix to distribute Pure Extract line of full spectrum oil vape and edible products throughout its nationwide network Partnership widens Pure Extracts’ footprint in Canada’s growing Cannabis 2.0 market Global extraction product market expected to reach $28.5 billion in next six years New agreement strengthens Pure Extracts’ sales channels as it looks towards international expansion There’s plenty of media coverage about increasing legalization of cannabis for medical and adult recreational use driving a broad market expected to reach $73.6 billion by 2027 (https://ibn.fm/ICOlM), but not as much about the cannabis extraction market that is growing at nearly…

FridayMar 05, 2021 1:30 pm

Missouri Introduces Legislation to Add Psychedelics to “Right to Try” Statute

Residents of the state of Missouri living with terminal, life-threatening or debilitating ailments may soon be able to legally access various psychedelic drugs under a new bill, whose objective is to broaden Missouri’s current Right to Try statute. A legislation introduced last month by Kansas City Republican Rep. Michael Davis would permit individuals who are seriously ill to use psychedelic substances such as ibogaine, MDMA, mescaline, psilocybin mushrooms, DMT and LSD, when all other approved treatment options have been exhausted and their doctor recommended it. Davis’ HB 1176 measure calls for the Right to Try law be expanded to include…

ThursdayMar 04, 2021 2:45 pm

Why Companies Should Manufacture Psychedelic Pharmaceuticals on Large Scale

The development of a new class of pharmaceutical medications made from psychedelic fungi and plants has brought medical science closer to making breakthroughs that address the global mental health crisis caused by the pandemic. These drugs have shown massive potential in the treatment of chronic depression. However, there are challenges that come with the development of standardized organic compounds to help treat more than a billion individuals globally for various mental health conditions. Frankly speaking, it’s complicated and costly to separate active ingredients in multi-compound organic substances. Globally, this has not been done on a broad scale anywhere, primarily for…

ThursdayMar 04, 2021 12:12 pm

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) Newly Acquired Subsidiary Achieves Earn-Out Milestone —Successful Synthesis of Multiple Tryptamine Derivatives

Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with Cybin Adelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health space Acquisition results in Cybin obtaining extensive intellectual property portfolio and product pipeline Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has announced that its recently acquired subsidiary, Adelia Therapeutics Inc., has achieved the earn-out milestones outlined for the time period in the contribution agreement between the two companies (https://ibn.fm/c6o2E). That milestone includes the successful synthesis of multiple tryptamine derivatives.…

WednesdayMar 03, 2021 1:00 pm

NYU Langone Health Sets Up Research Center for Psychedelic Medicine

Charitable donations and support valued at more than $10 million are aiding in the progression of NYU Langone Health’s study of psychedelic medicine. Langone Health will be launching a center for psychedelic medicine, which will focus on physician training and research in this burgeoning field. Once completed, the NYU Langone Center for Psychedelic Medicine, which will be under the Department of Psychiatry at NYU Langone, will center on a trio of transdisciplinary areas: preclinical, medicine and psychiatry research. In addition to this, the center will launch a Psychedelic Medicine Research Training Program, which will assist in the development of postdoctoral…

TuesdayMar 02, 2021 11:45 am

First Ever Psychedelic Therapy Clinic Launched in Calgary

Last week, the first psychedelic therapy clinic in the province launched in Calgary. The clinic is located in northwest Calgary and will be used as a mental health professional training center. Dr. Ravinder Bains, who is the facility’s chief medical officer, will be overseeing the psychedelic therapy. In an interview, David Harder, CEO of the ATMA Urban Journey Clinic, stated that the clinic was the result of years of a lot of studies and research. He noted that psychedelics did not work in the same way that standard psychotic medications or antidepressants worked. Harder explained that while conventional medications prescribed…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized